Download MendeleyCerastecin Inhibition of the Lipooligosaccharide Transporter MsbA to Combat Acinetobacter baumannii : From Screening Impurity to In Vivo Efficacy.
Skudlarek, J.W., Cooke, A.J., Mitchell, H.J., Babaoglu, K., Shaw, A.W., Tong, L., Nomland, A.B., Labroli, M., Sha, D., Mulhearn, J.J., Wu, C., Li, S.W., Beshore, D.C., Hughes, J.M.E., Jouffroy, M., Wang, H., Balibar, C.J., Painter, R.E., Shen, P., Lange, H.S., Ishchenko, A., Chen, Y.T., Klein, D.J., Tracy, R.W., Miller, R.R., Cabalu, T.D., Wu, Z., Leithead, A., Scapin, G., Hruza, A.W., Dzhekieva, L., Bukhtiyarova, M., Homsher, M.F., Xu, M., Bahnck-Teets, C., McKenney, D., Buevich, A.V., Liu, J., Zhang, L.K., Meng, T., Kelly, T., DiNunzio, E., Soisson, S., Cheng, R.K.Y., Hennig, M., Raheem, I., Walker, S.S.(2024) J Med Chem 67: 15620-15675
- PubMed: 39172133
- DOI: https://doi.org/10.1021/acs.jmedchem.4c01277
- Primary Citation of Related Structures:
9CSG, 9CSI - PubMed Abstract:
Acinetobacter baumannii , a commonly multidrug-resistant Gram-negative bacterium responsible for large numbers of bloodstream and lung infections worldwide, is increasingly difficult to treat and constitutes a growing threat to human health. Structurally novel antibacterial chemical matter that can evade existing resistance mechanisms is essential for addressing this critical medical need. Herein, we describe our efforts to inhibit the essential A. baumannii lipooligosaccharide (LOS) ATP-binding cassette (ABC) transporter MsbA. An unexpected impurity from a phenotypic screening was optimized as a series of dimeric compounds, culminating with 1 (cerastecin D), which exhibited antibacterial activity in the presence of human serum and a pharmacokinetic profile sufficient to achieve efficacy against A. baumannii in murine septicemia and lung infection models.
Organizational Affiliation:
Merck & Co., Inc., Rahway, New Jersey 07065, United States.
